A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

Overview

A Phase 1, single dose study with 8 cohorts of ascending doses designed to evaluate the safety and pharmacokinetics of MEDI0382 in healthy volunteers.

Full Title of Study: “A Phase 1, Single-ascending-dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: August 2015

Detailed Description

This is a first-time-in-humans (FTIH), randomized, double-blind study designed to evaluate the safety, tolerability, and PK of MEDI0382 administered as single-ascending SC doses to healthy subjects (age 18-45). Eight subjects per cohort will be enrolled in a total of 8 cohorts. The decision whether or not to dose escalate will be based upon data review by the Dose Escalation Committee (DEC). Within each cohort, the subjects will be randomized to MEDI0382 or placebo (3:1). Following screening, the study duration for each subject will be approximately 29 days, consisting of an inpatient evaluation period, and an outpatient follow-up period.

Interventions

  • Drug: MEDI0382
    • MEDI0382 administered subcutaneously
  • Drug: Placebo
    • Placebo administered subcutaneously

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo
    • Placebo administered subcutaneously
  • Experimental: MEDI0382
    • MEDI0382 administered subcutaneously

Clinical Trial Outcome Measures

Primary Measures

  • Number of subjects with adverse events as a measure of safety and tolerability of MEDI0382
    • Time Frame: 28 days post dosing
    • Treatment emergent adverse events (TEAEs) and serious adverse events (STEAEs)
  • Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382
    • Time Frame: 28 days post dosing
    • GI symptomatology (a composite of nausea and vomiting)
  • Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382
    • Time Frame: 28 days post dosing
    • Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory rate)
  • Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382
    • Time Frame: 28 days post dosing
    • 12 lead electrocardiogram including RR, PR, QRS, QT and QTc intervals
  • Number of subjects with Adverse events as a measure of safety and tolerability of MEDI0382
    • Time Frame: 28 days post dosing
    • Clinical laboratory assessments (serum chemistry, hematology, urinalysis)

Secondary Measures

  • Pharmacokinetics of MEDI0382, maximum plasma concentration (Cmax)
    • Time Frame: 72 hours postdose
    • This variable will be estimated for MEDI0382 where the data allow.
  • Pharmacokinetics of MEDI0382, area under the curve concentration (AUC)
    • Time Frame: 72 hours post dose
    • This variable will be estimated for MEDI0382 where the data allow.
  • Proportion of subjects with ADA to MEDI0382
    • Time Frame: 28 days post dose
    • This variable will be estimated for MEDI0382 where the data allow.

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy Volunteers, ages 18-45 – Must provide written informed consent – BMI >22 and <30 kg/m2 and body weight >70kg – Venous access suitable for multiple cannulations – Vital signs within normal specified ranges – Females must be non-lactating and non-childbearing potential – Males must practice 2 effective contraceptive measures if sexually active Exclusion Criteria:

  • Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product – History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs – History of cancer, with the exception of non-melanoma skin cancer – Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing – Positive Hepatitis B, Hepatitis C or HIV test or use of antiretroviral medications at screening. – Concurrent or previous use of a GLP-1 receptor agonist – Current or previous use of systemic corticosteroids within the past 28 days prior to screening – Use of any medicinal products or herbal preparations licensed for control of body weight or appetite is prohibited. – Known or suspected history of alcohol or drug abuse within the past 3 years. – Positive drug screen – Current smoker

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • MedImmune LLC
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.